Niagen Bioscience, Inc. financial data

Symbol
NAGE on Nasdaq
Location
10900 Wilshire Blvd, Suite 600, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 354 % +40.6%
Quick Ratio 57.5 % -13%
Debt-to-equity 48.8 % -44.3%
Return On Equity 35.5 %
Return On Assets 23.8 %
Operating Margin 14.3 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79.8M shares +5.03%
Common Stock, Shares, Outstanding 79.6M shares +5.45%
Entity Public Float 143M USD +76%
Common Stock, Value, Issued 79K USD +5.33%
Weighted Average Number of Shares Outstanding, Basic 79.2M shares +4.88%
Weighted Average Number of Shares Outstanding, Diluted 86.2M shares +14.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 116M USD +35.9%
Cost of Revenue 42.3M USD +26.2%
Research and Development Expense 5.43M USD -6.56%
Selling and Marketing Expense 32.1M USD +22.2%
General and Administrative Expense 19.8M USD -11.1%
Operating Income (Loss) 16.7M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3.74M USD
Income Tax Expense (Benefit) 128K USD
Net Income (Loss) Attributable to Parent 17.7M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 60.3M USD +118%
Accounts Receivable, after Allowance for Credit Loss, Current 9.66M USD +23.5%
Inventory, Net 14.4M USD +25.2%
Assets, Current 86.7M USD +75.8%
Operating Lease, Right-of-Use Asset 2.53M USD +22.4%
Intangible Assets, Net (Excluding Goodwill) 284K USD -34.7%
Other Assets, Noncurrent 405K USD +2.79%
Assets 91.5M USD +69.4%
Accounts Payable, Current 13.7M USD +68.8%
Accrued Liabilities, Current 7.38M USD -14.4%
Liabilities, Current 22.3M USD +25%
Contract with Customer, Liability, Noncurrent 2.67M USD -19.2%
Operating Lease, Liability, Noncurrent 2.33M USD +9.19%
Liabilities 27.3M USD +17.2%
Retained Earnings (Accumulated Deficit) -173M USD +9.28%
Stockholders' Equity Attributable to Parent 64.2M USD +109%
Liabilities and Equity 91.5M USD +69.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 7.88M USD +2572%
Net Cash Provided by (Used in) Financing Activities 3.11M USD
Net Cash Provided by (Used in) Investing Activities -32K USD +22%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 79.6M shares +5.45%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 11M USD +4465%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.5M USD +117%
Deferred Tax Assets, Valuation Allowance 44.3M USD -4.53%
Deferred Tax Assets, Gross 44.7M USD -4.43%
Operating Lease, Liability 3.29M USD +5.8%
Depreciation 158K USD -11.2%
Lessee, Operating Lease, Liability, to be Paid 3.89M USD +16.1%
Operating Lease, Liability, Current 957K USD -1.64%
Lessee, Operating Lease, Liability, to be Paid, Year Two 782K USD -13.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +4.23%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +14.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 606K USD +146%
Lessee, Operating Lease, Liability, to be Paid, Year Three 657K USD +33.8%
Deferred Tax Assets, Operating Loss Carryforwards 35.2M USD -4.11%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 338K USD -5.59%
Operating Lease, Payments 295K USD +224%
Additional Paid in Capital 237M USD +7.11%
Amortization of Intangible Assets 37K USD -2.63%
Deferred Tax Assets, Net of Valuation Allowance 386K USD +7.82%